Compounded semaglutide isn't always semaglutide

Published May 12, 2026 · Epioneum editorial · ~8 minute read

The cheapest GLP-1 program in our index costs $179 a month. The most expensive costs $1,350 for the same molecule. Or that’s the pitch. As of May 2025, the FDA disagrees. The federal shortage that made broad compounding legal ended in February 2025. The grace period for 503A pharmacies ran out April 22, 2025. And the FDA specifically warned that compounded products sold by many telehealth providers contain salt forms of semaglutide that the agency does not recognize as the same active ingredient as the FDA-approved drug.

This is what changed, what the 41 providers in our index did about it, and how to read a “compounded semaglutide” offer in 2026.

The price gap is real, but the gap stopped being about scarcity

Compounded semaglutide runs $179 to $299 a month across our index. Brand Wegovy through the same telehealth providers runs $1,300 to $1,400. A six-to-eight-times spread on what most patients are told is the same drug.

The mechanism behind that spread was the FDA’s drug shortage list. From late 2022 through February 2025, semaglutide was officially in shortage, which legally permitted compounding pharmacies to produce what the FDA calls “essentially a copy” of an approved drug under section 503A of the Federal Food, Drug, and Cosmetic Act. Compounding kept supply available when Novo Nordisk could not manufacture enough Wegovy and Ozempic. The price differential was the economic shadow of that legal exception.

The exception is no longer in force. On February 21, 2025, the FDA declared the semaglutide shortage resolved. State-licensed 503A pharmacies were given until April 22, 2025 to stop compounding routine copies. 503B outsourcing facilities had until May 22, 2025. On April 30, 2026 the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, with the public comment period open through June 29, 2026.

The legal door for broad compounded semaglutide closed twelve months ago. The price difference, in most cases, no longer reflects a supply gap. It reflects something else.

Compounded doesn’t mean generic

This is the part the cheap-tier providers don’t lead with.

A generic drug is an FDA-approved copy of a brand drug. The generic manufacturer must demonstrate bioequivalence to the original through clinical studies. The active ingredient must be chemically identical. The FDA reviews and approves the generic before it reaches a patient.

There is no generic semaglutide on the US market. None of the compounded products on a telehealth menu in 2026 are FDA-approved. The “compounded” label means a licensed pharmacist prepares the medication for a specific patient, customized in some way the approved drug isn’t: a different dose, a different formulation, sometimes a different chemical form. Compounded products are not reviewed by the FDA for safety, effectiveness, or quality before they reach a patient.

Compounding was never built to be a parallel manufacturing pathway for high-volume drugs. It exists to handle individual patient needs the approved drug can’t meet. The 2022-2025 shortage temporarily made it function like a parallel pathway, and the telehealth industry built infrastructure around that exception. When the FDA says “no generic semaglutide exists,” that’s accurate. When a telehealth provider implies you’re getting the same molecule cheaper, there’s a regulatory and chemical question to ask first.

Salt forms versus base form: the chemistry the FDA flagged

This is the technical core of the FDA’s safety alert on compounded semaglutide, and the reason “compounded semaglutide” doesn’t always mean what readers think.

Semaglutide as approved by the FDA exists as a peptide base form. That’s the active ingredient in Wegovy, Ozempic, and Rybelsus. Novo Nordisk’s manufacturing process produces this specific molecule, and the clinical trials that proved efficacy and safety were run against this specific molecule.

Many compounded products on the US market in 2024-2025 contained semaglutide sodium or semaglutide acetate, salt forms with different chemistry. The FDA stated plainly: “These salt forms are different active ingredients than that used in the FDA-approved drugs.”

What “different active ingredient” means in practice: the safety and efficacy data from the STEP-1 trial (14.9% body weight loss at 68 weeks) was run on the peptide base form. Whether the same outcome holds for the sodium or acetate salt forms has not been studied in any peer-reviewed clinical trial we could find. The agency received adverse event reports after patients used compounded products containing these salt forms.

A reasonable consumer reading “compounded semaglutide” on a telehealth menu would assume bioequivalence to Wegovy. That assumption is not supported by either FDA labeling or independent clinical data. The provider may be selling a peptide base compound (closer to Wegovy chemistry), a salt form, or some mixture. Most telehealth provider pages do not specify.

What the FDA actually did in 2025 and 2026

The regulatory escalation has been steady and specific. Worth tracking.

February 21, 2025: shortage declared resolved.

April 22, 2025: 503A compounding deadline. State-licensed pharmacies that kept compounding routine copies after this date moved outside the legal exception.

May 22, 2025: 503B outsourcing facility deadline. Large-batch federal compounders followed.

September 16, 2025: FDA issued more than 55 warning letters in a single day to online sellers of compounded GLP-1s, citing misleading direct-to-consumer advertising.

April 30, 2026: FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. If finalized after the June 29 comment window closes, the proposal forecloses bulk compounding pathways even if a future shortage were declared.

In parallel, Novo Nordisk has filed civil suits against multiple compounding pharmacies, and one large telehealth provider received an FDA warning letter in early 2026 specifically related to its compounded semaglutide marketing claims.

Of the 41 providers in our index, here’s what we observed since May 2025: 18 stopped selling compounded semaglutide and moved exclusively to brand or insurance-facilitated paths. 14 continued selling under a “personalized formulation” framing, claiming each prescription is medically customized rather than a copy of Wegovy. 9 explicitly state their compounded product uses the peptide base form. The rest do not specify, or use language that implies but does not confirm.

Why $179 a month is still possible: the medical-need exception

The legal pathway the surviving budget-tier providers point to is the FDA’s narrow 503A exception for compounded products that are not essentially copies of an approved drug. Two scenarios fit cleanly:

1. A patient has a documented allergy to an excipient (a non-active ingredient) in the FDA-approved Wegovy. The compounded version omits or substitutes that excipient. Legitimately a different product.
2. A patient needs a dose strength that isn’t commercially available. The approved Wegovy doses are 0.25, 0.5, 1.0, 1.7, and 2.4 mg weekly. A patient prescribed 0.1 mg (microdosing protocols) or 1.2 mg (a between-step titration dose) could legitimately receive a compounded product.

What’s harder to defend: providers offering compounded semaglutide to every patient at standard doses with no documented allergy or unique medical need. The FDA has stated this practice is outside the exception. The legal exposure sits with the provider and the pharmacy, not with the patient. But if the provider gets sanctioned, your supply gets disrupted.

If a provider in our index sells you compounded semaglutide at $179 a month in 2026, ask which exception applies to you specifically. If the answer is “we customize every patient’s dose,” request the documentation. If they can’t produce it, the offer is regulatorily fragile.

Who this matters for, and who it doesn’t

Compounded paths still make sense for:

• Patients with documented excipient allergies who couldn’t tolerate FDA-approved Wegovy. Real and uncommon.
• Patients on legitimate microdosing protocols supervised by a clinician.
• Patients in dose-titration windows where the approved increment doesn’t match their physiology.

Brand-name paths make sense for:

• Patients who can access insurance coverage. About 27% of those who qualify on paper succeed in getting Wegovy or Zepbound covered, per claims data we’ve tracked across the index.
• Patients without documented medical need for customization.
• Patients who want the FDA bioequivalence guarantee and the manufacturing-quality oversight that comes with it.
• Patients who plan to stay on GLP-1 for the long haul and want the most regulatorily durable path.

For a patient who fits the brand-name profile and is paying compounded prices anyway, the savings may not survive what happens after June 29, 2026 when the FDA’s exclusion proposal moves to a final decision.

The price gap between compounded and brand is real, but the gap is no longer about scarcity. It’s about regulation, chemistry, and whether your provider can document why your specific prescription required customization. If you’re choosing today, the question isn’t compounded versus brand. It’s whether you qualify for the narrow 503A exception, and whether your provider can show you how.

For our take on which providers handle that question transparently versus which finesse it, see our methodology and the provider index.

This guide is informational only. It is not medical advice. Consult a US-licensed clinician before starting, changing, or stopping any GLP-1 medication. If you spot a factual error, corrections@epioneum.com.